Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Review

Correlation between fertility drugs use and malignant melanoma incidence: the state of the art

Authors: Federica Tomao, Anselmo Papa, Giuseppe Lo Russo, Sara Zuber, Gian Paolo Spinelli, Luigi Rossi, Davide Caruso, Natalie Prinzi, Valeria Stati, Pierluigi Benedetti Panici, Silverio Tomao

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

The relationship between fertility, reproductive hormones, and risk of malignant melanoma has acquired much interest in recent years. Melanocytes are hormonally responsive cells, and some in vitro studies demonstrated that estrogen hormones stimulate the growth of melanocytes. Moreover, estrogen receptors have been identified in melanoma cells, as well as in melanocytic nevi and in normal skin. Some evidences suggest a possible link between fertility treatments and the increased risk of malignant melanoma. This article addresses this association through a scrupulous search of the literature published thus far. The aim of this review is to determine the incidence of malignant melanoma in women treated with fertility drugs and to examine if the exposure to fertility treatments really increases the risk of malignant melanoma. In particular, our analysis focused on the different types of drugs and different treatment schedules used. Finally, this study provides additional insights regarding the long-term relationships between fertility drugs and the risk of malignant melanoma.
Literature
1.
Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82(3):364–80.PubMedCrossRef
2.
3.
Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol. 2012;30(18):2240–7.PubMedCrossRef
4.
Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131(3):719–26.PubMedCrossRef
5.
Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175(6):437–44.PubMedCrossRef
6.
Conybeare RC. Malignant melanoma and pregnancy: report of 3 cases. Obstet Gynecol. 1964;24:451–4.PubMed
7.
Jhaveri MB, Driscoll MS, Grant-Kels JM. Melanoma in pregnancy. Clin Obstet Gynecol. 2011;54(4):537–45.PubMedCrossRef
8.
Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol. 2007;165(11):1265–70.PubMedCrossRef
9.
Houghton AN, Flannery J, Viola MV. Malignant melanoma of the skin occurring during pregnancy. Cancer. 1981;48(2):407–10.PubMedCrossRef
10.
Lens MB, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol. 2004;22(21):4369–75.PubMedCrossRef
11.
Silipo V, De Simone P, Mariani G, Buccini P, Ferrari A, Catricala C. Malignant melanoma and pregnancy. Melanoma Res. 2006;16(6):497–500.PubMedCrossRef
12.
O' Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer. 2005;103(6):26–1217.CrossRef
13.
Zhou JH, Kim KB, Myers JN, Fox PS, Ning J, Bassett RL, et al. Immunohistochemical expression of hormone receptors in melanoma of pregnant women, non pregnant women, and men. Am J Dermatopathol. 2014;36(1):74–9.PubMedCentralPubMedCrossRef
14.
Schmidt AN, Nanney LB, Boyd AS, King Jr LE, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15(12):971–80.PubMedCrossRef
15.
de Giorgi V, Mavilia C, Massi D, Gozzini A, Aragona P, Tanini A, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol. 2009;145(1):30–6.PubMedCrossRef
16.
17.
Pfahlberg A, Hassan K, Wille L, Lausen B, Gefeller O. Systematic review of case–control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 1997;25(3–4):309–15.PubMed
18.
Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998;138(1):122–4.PubMedCrossRef
19.
Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case–control studies of melanoma and oral contraceptive use. Br J Cancer. 2002;86(7):1085–92.PubMedCentralPubMedCrossRef
20.
Leslie KK, Espey E. Oral contraceptives and skin cancer is there a link? Am J Clin Dermatol. 2005;6(6):349–55.PubMedCrossRef
21.
Gandini S, Iodice S, Koomen ER, Pietro AD, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–17.PubMedCrossRef
22.
Pack GT, Scharnagel IM. The prognosis of malignant melanoma in pregnant woman. Cancer. 1951;4(2):324–34.PubMedCrossRef
23.
Byrd BF, McGanity WJ. The effect of pregnancy on the clinical course of malignant melanoma. South Med J. 1954;47(3):196–200.PubMedCrossRef
24.
Sutherland CM, Loutfi A, Mather FJ, Carter RD, Krementz ET. Effect of pregnancy upon malignant melanoma. Surg Gynecol Obstet. 1983;157(5):443–6.PubMed
25.
Trapeznikov NN, Khasanov SR, Iavorskiĭ VV. Melanoma of the skin and pregnancy. Vopr Onkol. 1987;33(6):40–6.PubMed
26.
27.
McManamny DS, Moss AL, Pocock PV, Briggs JC. Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynaecol. 1989;96(12):1419–23.PubMedCrossRef
28.
Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL. Prognostic significance of pregnancy in stage I melanoma. Arch Surg. 1989;124:1227–31.PubMedCrossRef
29.
Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case–control study of cutaneous malignant melanoma. III Hormonal and reproductive factors in women Int J Cancer. 1988;42:821–4.PubMed
30.
Lambe M, Thörn M, Sparén P, Bergström R, Adami HO. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Melanoma Res. 1996;6:147–53.PubMedCrossRef
31.
Karagas MR, Zens MS, Stukel TA, Swerdlow AJ, Rosso S, Osterlind A, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes and Control. 2006;17(1):11–9.PubMedCrossRef
32.
Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe Jr L. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212–24.PubMedCrossRef
33.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril. 2004;82 Suppl 1:S90-6.
34.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013;100(2):341–8.CrossRef
35.
Diedrich K, Felberbaum R. New approaches to ovarian stimulation. Hum Reprod. 1998;13 Suppl 3:1–13.PubMedCrossRef
36.
Leibowitz D, Hoffman J. Fertility drug therapies: past, present, and future. J Obstet Gynecol Neonatal Nurs. 2000;29(2):201–10.PubMedCrossRef
37.
Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85(2):277–84.PubMedCrossRef
38.
Hilliard TS, Modi DA, Burdette JE. Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium. Int J Mol Sci. 2013;14(3):4762–82.PubMedCentralPubMedCrossRef
39.
Lo Russo G, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, et al. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther. 2013;13(2):149–57.PubMedCrossRef
40.
Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet. 2013;287(6):1187–204.PubMedCrossRef
41.
Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):106–23.PubMedCrossRef
42.
Tomao F, Lo Russo G, Spinelli GP, Tomao S. Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem. Curr Opin Obstet Gynecol. 2014;26(3):130–7.PubMedCrossRef
43.
Tomao F, Lo Russo G, Spinelli GP, Stati V, Prete AA, Prinzi N, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res. 2014;8:7–51.
44.
Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125(5):780–90.PubMed
45.
Brinton LA, Melton 3rd LJ, Malkasian Jr GO, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol. 1989;129(4):712–22.PubMed
46.
Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res. 1995;5(2):123–7.PubMedCrossRef
47.
Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995–1000.PubMedCrossRef
48.
Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11):1038–42.PubMedCrossRef
49.
Young P. Purdie 0, Jackman L, Molloy 0. Green A A study of infertility treatment and melanoma Melanoma Res. 2001;11(5):535–41.
50.
Althuis MD, Scaccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol. 2005;193(3 Pt 1):668–74.PubMedCrossRef
51.
Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control. 2008;19(7):759–65.PubMedCrossRef
52.
Silva Idos S, Wark PA, McCormack VA. Mayer 0, Overton C, Little V, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort Br J Cancer. 2009;100(11):1824–31.PubMed
53.
Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC. Manor 0, et al. Cancer risk after exposure to treatments for ovulation induction Am J Epidemiol. 2009;169(3):365–75.PubMed
54.
Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9,175 Finnish women treated for infertility. Hum Reprod. 2012;27(4):1149–55.PubMedCrossRef
55.
Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. Association between in-vitro fertilization, birth and melanoma. Melanoma Res. 2013;23(6):489–95.PubMedCrossRef
56.
Snell RS, Bischitz PG. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol. 1960;35:73–82.PubMedCrossRef
57.
Thornton M, Taylor AH, Mulligan K, AI-Azzawi F, Lyon CC, O'Driscoll J, et al. The distribution of estrogen receptor beta is distinct to that of estrogen receptor alpha and the androgen receptor in human skin and the pilosebaceous unit. J Investig Dermatol Symp. 2003;8(1):3–100.
58.
Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35(4):215–21.PubMedCrossRef
59.
Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol. 2011;173(10):1192–202.PubMedCrossRef
60.
eskanich 0, Hunter OJ, Willett WC, Spiegelman 0, Stampfer MJ, Speizer FE, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999;81 (5):918–23.
61.
Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study. Ann Oncol. 2009;20(2):358–64.PubMedCrossRef
62.
63.
Gandini S, Sera F, Callaruzza MS, Pasquini P. Picconi 0, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure Eur J Cancer. 2005;41(1):45–60.PubMed
64.
Veierød MB, Weiderpass E, Thom M, Hansson J, Lund E, Armstrong B, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst. 2003;95(20):1530–8.PubMedCrossRef
65.
Nielsen K, Masback A, Olsson H, Ingvar C. A prospective, population-based study of 40000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. Int J Cancer. 2012;131(3):706–15.PubMedCrossRef
66.
Levine H, Afek A, Shamiss A, Derazne E. Tzur 0, Astman N, et al. Country of origin, age at migration and risk of cutaneous melanoma: a migrant cohort study of 1,100,000 Israeli men. Int J Cancer. 2013;133(2):486–94.PubMedCrossRef
67.
Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online. 2009;19(4):456–71.PubMedCrossRef
68.
Polyzos NP, Tzioras S, Mauri D, Tsappi M, Cortinovis I, Tsali L, et al. Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: a systematic review and meta-analysis. Obstet Gynecol Surv. 2008;63(7):472–9.PubMedCrossRef
Metadata
Title
Correlation between fertility drugs use and malignant melanoma incidence: the state of the art
Authors
Federica Tomao
Anselmo Papa
Giuseppe Lo Russo
Sara Zuber
Gian Paolo Spinelli
Luigi Rossi
Davide Caruso
Natalie Prinzi
Valeria Stati
Pierluigi Benedetti Panici
Silverio Tomao
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2230-4

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis

Research Article

Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial–mesenchymal transition (EMT) in SCC15 cells

Research Article

Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis

Research Article

ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells

Research Article

miR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor

Review

Extracellular vesicles shed by glioma cells: pathogenic role and clinical value

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits